Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Patients expected to receive a 500 mg/m2 of Leucovorin by iv & 500 mg/m2 of Fluorouracil
(5FU) by iv bolus for their Colorectal Cancer. The patients will receive a one-hour infusion
of TK-90 or equivalent TK-90 placebo depending on randomization at 5 hours & 11 hours post
5-FU iv bolus. This treatment cycle will continue weekly for 6 weeks. The TK112690 dose will
be 45 mg/kg.